Virtus ETF Advisers LLC Karuna Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$161.01 - $317.85 $1,449 - $2,860	9 Added 2.17%	423 $133,000
Q3 2023 Nov 07, 2023	SELL	$164.66 - $218.08 $6,421 - $8,505	-39 Reduced 8.61%	414 $70,000
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $7,758 - $10,569	-44 Reduced 8.85%	453 $98,000
Q1 2023 May 15, 2023	SELL	$161.33 - $204.36 $30,330 - $38,419	-188 Reduced 27.45%	497 $90,000
Q4 2022 Feb 14, 2023	SELL	$191.53 - $236.82 $69,908 - $86,439	-365 Reduced 34.76%	685 $134,000
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $247 - $554	2 Added 0.19%	1,050 $236,000
Q2 2022 Aug 12, 2022	SELL	$93.97 - $143.33 $29,976 - $45,722	-319 Reduced 23.34%	1,048 $133,000
Q1 2022 May 16, 2022	SELL	$98.9 - $132.37 $8,307 - $11,119	-84 Reduced 5.79%	1,367 $173,000
Q4 2021 Feb 14, 2022	SELL	$110.64 - $159.4 $21,353 - $30,764	-193 Reduced 11.74%	1,451 $190,000
Q3 2021 Nov 15, 2021	SELL	$101.2 - $125.87 $8,500 - $10,573	-84 Reduced 4.86%	1,644 $201,000
Q2 2021 Aug 10, 2021	SELL	$107.45 - $135.95 $156,662 - $198,215	-1,458 Reduced 45.76%	1,728 $197,000
Q1 2021 May 17, 2021	BUY	$95.46 - $133.08 $6,109 - $8,517	64 Added 2.05%	3,186 $383,000
Q4 2020 Feb 12, 2021	SELL	$75.23 - $109.23 $15,046 - $21,846	-200 Reduced 6.02%	3,122 $317,000
Q3 2020 Nov 13, 2020	SELL	$71.31 - $109.74 $31,661 - $48,724	-444 Reduced 11.79%	3,322 $257,000
Q2 2020 Aug 05, 2020	SELL	$62.14 - $117.21 $108,745 - $205,117	-1,750 Reduced 31.73%	3,766 $420,000
Q1 2020 May 14, 2020	SELL	$60.41 - $115.92 $47,723 - $91,576	-790 Reduced 12.53%	5,516 $397,000
Q4 2019 Feb 13, 2020	BUY	$11.44 - $123.99 $72,140 - $781,880	6,306 New	6,306 $475,000

Others Institutions Holding KRTX

# of Institutions

Shares Held

332K

Call Options Held

Put Options Held

View Full List

About Karuna Therapeutics, Inc.

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

More about KRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account